Risk minimisation materials: Zolgensma (onasemnogene abeparvovec) solution for infusion

This healthcare professional letter advises of the risk and management of thrombotic microangiopathy, which has been reported in spinal muscular atrophy patients treated with onasemnogene abeparvovec, particularly in the first weeks of treatment.

Source:

electronic Medicines compendium